Heart failure in 2005;La insuficiencia cardíaca en el año 2005

Revista Espanola de Cardiologia

Volumn 59, Issue SUPPL.1, 2006, Pages 55-65

  Jiménez Navarro, Manuel F ^a   Martínez, Javier Díez ^b,c   Delgado Jiménez, Juan F ^d   Crespo Leiro, María G ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e Unidad de Insuficiencia Cardíaca Y Trasplante Cardíaco   (Spain)

Author keywords

Cardiac resynchronization therapy; Heart failure; Heart transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; OKT 3;

CARDIAC GRAFT REJECTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; EXTRACELLULAR MATRIX; HEART ASSIST DEVICE; HEART FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; PATHOPHYSIOLOGY; PREVALENCE; REVIEW;

EID: 34249996212     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13084449     Document Type: Article

References (91)

1. Crespo MG, Jiménez M, Pulpón LA, Cuenca JJ, Muñoz R, Fernández-Avilés F. La insuficiencia cardíaca en el año 2004. Rev Esp Cardiol Supl. 2005;5:35A-44.
2. Nieminen M, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Rev Esp Cardiol. 2005;58:1062-92.
3. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Rev Esp Cardiol. 2005; 58:1062-92.
4. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:1116-43.
5. Adamson PB, Abraham WT, Lowe C, Reynolds D. The evolving challenge of heart failure manegement. A call for a new curriculum for training heart failure specialistis. J Am Coll Cardiol. 2004;44:1354-7.
6. Konstam MA. Heart failure training. A call for an integrative, patient-focused approach to an emerging cardiology subspecialty. J Am Coll Cardiol. 2004;44:1361-2.
7. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden. Eur Heart J. 2004;25:300-7.
8. Rumsfield JS, Masoudi FA. Sex differences: implications for heart failure care. Eur Heart J. 2004;25:101-3.
9. Lupón J, Urrutia A, González B, Herreros J, Altimir S, Coll R, et al. Significado pronóstico de los valores de hemoglobina en pacientes con insuficiencia cardíaca. Rev Esp Cardiol. 2005;58:48-53.
10. Roig E. La anemia en la insuficiencia cardíaca. ¿Es un marcador de gravedad o un objetivo terapéutico? Rev Esp Cardiol. 2005;58:10-2.
11. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317-27.
12. Zile MR, Baicu CF, Gaasch W. Diastolic Heart Failure-Abnormalities in Active Relaxation and Passive Stiffness of the Left Ventricle. N Engl J Med. 2004;350:1953-9.
13. Fukuta H, Sane D, Brucks S, Little W. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation. 2005;112:357-63.
14. Lavie CJ, Mehra MR, Milani RV. Obesity and heart failure prognosis: paradox or reverse epidemiology. Eur Heart J. 2005;26:5-7.
15. Rivera M, Cortés R, Portolés M, Valero R, Sancho-Tello MJ, Martínez-Dolz L, et al. Relación de los valores plasmáticos de big endotelina-1 con NT-proBNP y la función ventricular de pacientes con insuficiencia cardíaca. Rev Esp Cardiol. 2005;58:278-84.
16. Sitges M, Roig E, Morales M, Azqueta M, Pérez Villa F, Paré V, et al. La disfunción endotelial periférica en la miocardiopatía dilatada idiopática se asocia con mayor disfunción ventricular y concentraciones plasmáticas elevadas de factor de necrosis tumoral. Rev Esp Cardiol. 2005;58:477-83.
17. Mann DL, Bristow MR. Mechanisms and models in heart failure. Circulation. 2005;111:2837-49.
18. González A, Fortuño MA, Querejeta R, Ravassa S, López B, López N, et al. Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovasc Res. 2003;59:549-62.
19. Foo Rs-Y, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest. 2005;115:565-72.
20. Fortuño MA, González A, Ravassa S, López B, Díez J. Clinical implications of apoptosis in hypertensive heart disease. Am J Physiol Heart Circ Physiol. 2003;284:H1495-506.
21. Van Empel VPM, Bertrand ATA, Hofstra L, Crijins HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res. 2005;67:21-9.
22. Camors E, Monceau V, Charlemagne D. Annexins and Ca2 + handling in the heart. Cardiovasc Res. 2005;65:793-802.
23. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest. 2005;115:547-55.
24. Matsui T, Rosenzweig A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol. 2005;38:63-71.
25. López N, Díez J, Fortuño MA. Characterization of the protective effect of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine. 2005;30:282-92.
26. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T. Augmented expression of cardiotrophin-1 in failing human heart is accompanied by diminished glycoprotein 130 receptor abundance. Ciculation. 2002;106:1442-6.
27. Garg S, Narula J, Chandrashekhar Y. Apoptosis and heart failure: clinical relevance and therapeutic target. J Mol Cell Cardiol. 2005;38:73-9.
28. Morissette MR, Rosenzweig A. Targeting survival signaling in heart failure. Curr Opin Pharmacol. 2005;5:165-70.
29. Dimmeler S, Zeiher AM, Schneider MD. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest. 2005;115:572-83.
30. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-6.
31. Urbanek K, Torella D, Sheik F, De Angelis A, Nurzynska D, Silvestri F, et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci USA. 2005;102:8692-7.
32. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin. 2000;18:435-42.
33. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol. 2004;286:H1-10.
34. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. Herz. 2003;28:744-53.
35. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944-9.
36. González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr Opin Nephrol Hypertens. 2005;14:428-34.
37. Querejeta R, López B, González A, Sánchez E, Larman M, Martínez Ubago JL, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation. 2004;110:1263-8.
38. Jiménez-Navarro MF, Gómez-Doblas JJ, Cabrera-Bueno F, Cruz-Ocaña E, Rodríguez-Bailón I, Ruiz-Galdón M, et al. Síntesis de colágeno e insuficiencia cardíaca. Rev Esp Cardiol. 2005;58:975-8.
39. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-35.
40. Cosín J, Díez J; on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-13.
41. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J; SENIORS Investigators. Randomized Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
42. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57.
43. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure. Circulation. 2005;111:1487-91.
44. Teerlink JR, Massie B. Nesiritide and Worsening of Renal Function: The Emperor's New Clothes? Circulation. 2005;111:1459-1.
45. Topol EJ. Nesiritide: not verified. N Engl J Med. 2005;343:246-53.
46. a Sesión Científica Anual del American Collage of Cardiology. Rev Esp Cardiol. 2005;58:666-78.
47. Congreso Europeo de Cardiología 2005. Disponible en: http://www.escardio.org/knowledge/congresses/CongressReports/hot/hot2005/ hotline1.htm
48. Salvador MJ, Sebaoun A, Sonntag F, Blanch P, Silber S, Aznar J, et al. Estudio europeo del tratamiento ambulatorio de la insuficiencia cardíaca realizado por cardiólogos. Rev Esp Cardiol. 2004;57:1170-8.
49. Grigorian L, Varela-Román A, Virgos A, Rigueiro P, García Acuña J, González-Juanatey JR. Evolución a largo plazo de la prescripción de fármacos en pacientes hospitalizados por insuficiencia cardiaca congestiva. Influencia del patrón de disfunción. Rev Esp Cardiol. 2005;58:381-8.
50. Anguita M; investigadores registro BADAPIC. Características clínicas, tratamiento y morbimortalidad a corto plazo de pacientes con IC controladas en Consultas Específicas de IC. Resultados del registro BAPADIC. Rev Esp Cardiol. 2004;57:1159-69.
51. Morcillo C, Valderas JM, Aguado O, Delas J, Sort D, Pujadas R, et al. Evaluación de una intervención domiciliaria en pacientes con insuficiencia cardíaca. Resultados de un estudio aleatorizado. Rev Esp Cardiol. 2005;58:618-25.
52. Lupon J, Parajon T, Urrutia A, González B, Jerreros J, Altimir S, et al. Reducción de los ingresos por insuficiencia cardíaca en el primer año de seguimiento en una unidad multidisciplinaria. Rev Esp Cardiol. 2005;58:374-80.
53. Atienza F, Anguita M, Martínez-Alzamora N, Osca J, Ojeda S, Almenar L, et al. Multicenter randomized trial of comprehensive hospital discharge and outpatient heart failure manegement program. Eur J Heart Failure. 2004;6:643-52.
54. Gonseth J, Guallar-Castillón P, Banegas JR, Rodríguez- Artalejo F. The effectiveness of disease management programmes in reducing hospital re-admission in older patients with heart failure: a systematic review and meta-analysis of published reports. Eur Heart J. 2004;25:1570-95.
55. Gustafsson F, Arnold J. Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. Eur Heart J. 2004;25:1596-604.
56. Rumsfeld JS, Masoudi FA. Heart failure disease management works, but will it succeed? Eur Heart J. 2004;25:1565-7.
57. Galbreath AD, Krasuski RA, Smith B, Stajduhar K, Kwan MD, Ellir R, et al. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation. 2004;110:3518-24.
58. Fonarrow G. Heart Failure Disease Management Program. Not a class effect. Circulation. 2004;110:3506-8.
59. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission A systematic review of randomized trials. J Am Coll Cardiol. 2004;44:810-9.
60. Ojeda S, Anguita M, Delgado M, Atienza F, Rus C, Granados AL, et al. Short- and long-term results of a programme for the prevention of readmissions and mortality in patients with heart failure: are effects maintained after stopping the programme? Eur J Heart Fail. 2005;7:921-6.
61. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
62. Molhoek SG, Bax JJ, Bleeker GB, Holman ER, Vane L, Bootsma M, et al. Long-term follow-up of cardiac resynchronization therapy in patients with end-stage heart failure. J Cardiovasc Electrophysiol. 2005;16:701-7.
63. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. N Engl J Med. 2005;352:225-37.
64. Jauhar S. Slotwiner DJ. The Economics of ICDs. N Engl J Med. 2004;351:2542-4.
65. Sánchez V, Cavero MA, Delgado JF, Pulpón LA. Terapia de resincronización cardíaca: punto de vista del cardiólogo clínico. Rev Esp Cardiol. 2005;5:53B-9.
66. Lecoq G, Leclercq C, Leray E, Crocq C, Alonso C, De Place C, et al. Clinical and electrocardiographic predictors of a positive response to cardiac resynchronization therapy in advanced heart failure. Eur Heart J. 2005;26:1094-100.
67. Zhang Q, Yu C-M, Fung JW-H, Zhang Y, Chan Y-S, Chan HCK, et al. Assessment of the effect of cardiac resynchronization therapy on intraventricular mechanical synchronicity by regional volumetric changes. Am J Cardiol. 2005;95:126-9.
68. Yu CM, Zhang Q, Fung JWH, Chan HCK, Chan YS, Yip GWK, et al. A novel tool to assess systolic asynchrony and identify responders of cardiac resynchronization therapy by tissue synchronization imaging. J Am Coll Cardiol. 2005;45:677-84.
69. Pitzalis MV, Iacoviello M, Romito R, Guida P, De Tommasi E, Luzzi G, et al. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol. 2005;45:65-9.
70. Yu CM, Abraham WT, Bax J, Chung E, Fedewa M, Ghio S, et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)-study design. Am Heart J. 2005;149:600-5.
71. Lazar R, Shapiro P, Jaski B, Parides M, Bourge R, Watson J, et al. Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience. Circulation. 2004;109:2423-7.
72. Lietz K, Miller LW. Hill left-ventricular assist device therapy replace heart transplantation in the foreseeable future? Curr Opin Cardiol. 2005;20:132-7.
73. Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med. 2004;351:859-67.
74. Dor V. Left ventricular reconstruction: the aim and the reality alter twenty years. J Thorac Cardiovasc Surg. 2004;128:17-20.
75. McConnell PI, Michler RE. Clinical trials in the surgical management of congestive heart failure: surgical ventricular restoration, autologous skeletal myoblast and stem cell cardiomyoplasty. Cardiology. 2004;101:48-60.
76. Baumgartner WA, Burrows S, Del Nido PJ, Gardner TJ, Goldberg S, Groman RC, et al. Recommendations of the National Heart, Lung and Blood Institute Working Group on future direction in cardiac surgery. Circulation. 2005;111:3007-13.
77. Almenar Bonet L. Registro Español de Trasplante Cardíaco. XV Informe Oficial (1984-2003). Rev Esp Cardiol. 2004;57:1197-204.
78. Wood K, Becker B, McCartney J, D'Alessandro A, Coursin D. Care of the potential organ donor. N Engl J Med. 2004;351: 2730-9.
79. Radovancevic B, Vrtovec B, Thomas C, Croitoru M, Myers T, Radovancevic R, et al. Nitric oxide versus prostaglandin E1, for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant. 2005;24:690-5.
80. Nguyen V, Cantarovich M, Cecere R, Giannetti N. Tricuspid regurgitation after cardiac transplantation: How many biopsies are too many? J Heart Lung Transplant. 2005;24:S227-31.
81. Marboe C, Billingham M, Eisen H, Deng M, Baron H, Mehra M, et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005;24:S219-26.
82. Mehra M. The emergence of genomic and proteomic biomarkers in heart transplantation. J Heart Lung Transplant. 2005;24:S213-8.
83. Horwitz P, Tsai E, Putt M, Gilmore J, Lepore J, Parmacek M, et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation. 2004;110:3815-21.
84. Evans R, Williams G, Baron H, Deng M, Eisen H, Hunt S, et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am J Transplant. 2005;5:1553-8.
85. Meiser B, Reichart B, Adamidis I, Überfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant. 2005;5:827-31.
86. Eisen H, Tuzcu E, Dorent R, Kobashigawa J, Mancini D, Valantine von Kaeppler H, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplants recipients. N Engl J Med. 2003;349:847-58.
87. Starling R, Hare J, Hauptman P, McCurry K, Mayer H, Kovarik J, et al. Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant. 2004;4:2126-31.
88. Eisen H, Kobashigawa J, Keogh A, Bourge R, Renlund D, Mentzer R, et al. Three years results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517-25.
89. Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351:2715-29.
90. Hershberger R, Starling R, Eisen H, Bergh C, Kormos R, Love R, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705-13.
91. Rodriguez-Lambert J, Crespo-Leiro M, Segovia J, Almenar L, Roig E, Gómez-Sánchez M, et al. Final results of the study of safety and tolerability of Simulect (basiliximab) versus OKT3 in heart transplantation. J Heart Lung Transplant. 2004;23:S112.